AgingResearch.News

TrialPhase 1Not yet recruiting

[11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction (NEURO-HF)

Neuroinflammation as a Therapeutic Target in Heart Failure-Related Cognitive Decline: A Feasibility PET Study

Sponsor
Stony Brook University (Academic or other)
Enrolment
18 planned
Conditions
Heart Failure With Reduced Ejection Fraction; Cognitive Impairment, Mild; Neuroinflammation; Vascular Contributions to Cognitive Impairment and Dementia (VCID)
Interventions
[11C]PS13: [carbon-11]PS13; COX-1 PET radioligand; Sacubitril-Valsartan
Ages
adults, older adults
Registry
NCT07856043

From the registry

Heart failure reduces the amount of blood the heart pumps, which can lead to memory and thinking problems in many patients. One possible reason is that heart failure triggers brain inflammation, a process in which certain brain immune cells (called microglia) become overactive. A heart failure medication called sacubitril-valsartan has been shown to reduce the risk of developing dementia, but it is not known whether this is because it reduces brain inflammation. This study uses a new experimental brain scan drug called \[11C\]PS13 (PS13) to measure brain inflammation directly and non-invasively, using a technique called positron emission tomography (PET). PS13 sticks to a molecule called COX-1, which is found mainly in brain immune cells (microglia). By measuring how much PS13 accumulates in the brain, researchers can estimate how much brain inflammation is present. In this pilot study, 18 patients with heart failure and mild memory or thinking problems who are being started on sacubitril-valsartan by their cardiologist (as standard clinical care) will undergo two brain PET scans:…

Primary outcomes

  • Change in [11C]PS13 Total Distribution Volume (VT) in Global Gray Matter
Full record on ClinicalTrials.gov